A phase 1 trial of the anti-KIR antibody IPH 2101 in patients with relapsed / refractory multiple myeloma
暂无分享,去创建一个
M. Caligiuri | C. Hofmeister | S. Jagannath | D. Benson | S. Farag | Y. Efebera | R. Abonour | P. André | S. Padmanabhan | A. Suvannasankha | J. Tiollier | C. Bakan